Glucose-dependent insulinotropic polypeptide (GIP)
Molecular Metabolism,
Год журнала:
2025,
Номер
95, С. 102118 - 102118
Опубликована: Фев. 28, 2025
Glucose-dependent
insulinotropic
polypeptide
(GIP)
was
the
first
incretin
identified
and
plays
an
essential
role
in
maintenance
of
glucose
tolerance
healthy
humans.
Until
recently
GIP
had
not
been
developed
as
a
therapeutic
thus
has
overshadowed
by
other
incretin,
glucagon-like
peptide
1
(GLP-1),
which
is
basis
for
several
successful
drugs
to
treat
diabetes
obesity.
However,
there
rekindling
interest
biology
recent
years,
great
part
due
pharmacology
demonstrating
that
both
GIPR
agonism
antagonism
may
be
beneficial
treating
obesity
diabetes.
This
apparent
paradox
reinvigorated
field,
led
new
lines
investigation,
deeper
understanding
GIP.
In
this
review,
we
provide
detailed
overview
on
multifaceted
nature
discuss
implications
signal
modification
various
diseases.
Following
its
classification
hormone,
emerged
pleiotropic
hormone
with
variety
metabolic
effects
outside
endocrine
pancreas.
The
numerous
render
interesting
candidate
development
pharmacotherapies
obesity,
diabetes,
drug-induced
nausea
bone
neurodegenerative
disorders.
Язык: Английский
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
Nature Metabolism,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 29, 2025
Язык: Английский
GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice
Nature Metabolism,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 29, 2025
Язык: Английский
The role of GIPR in food intake control
Frontiers in Endocrinology,
Год журнала:
2025,
Номер
16
Опубликована: Март 17, 2025
Glucose-dependent
insulinotropic
polypeptide
(GIP)
is
one
of
two
incretin
hormones
playing
key
roles
in
the
control
food
intake,
nutrient
assimilation,
insulin
secretion
and
whole-body
metabolism.
Recent
pharmacological
advances
clinical
trials
show
that
unimolecular
co-agonists
target
receptors
for
incretins
-
GIP
glucagon-like
peptide
1
(GLP-1)
offer
more
effective
treatment
strategies
obesity
type
2
diabetes
mellitus
(T2D)
compared
with
GLP-1
receptor
(GLP1R)
agonists
alone,
suggesting
previously
underappreciated
regulating
intake
body
weight.
The
mechanisms
by
which
regulates
energy
balance
remain
controversial
as
both
agonism
antagonism
(GIPR)
produce
weight
loss
improve
metabolic
outcomes
preclinical
models.
studies
have
shown
GIPR
signalling
central
nervous
system
(CNS),
especially
regions
brain
regulate
balance,
essential
its
action
on
appetite
regulation.
This
finding
has
sparked
interest
understanding
engages
circuits
to
reduce
In
this
review,
we
present
knowledge
around
actions
regulation
potential
GIPR/GLP1R
may
balance.
Язык: Английский
Unravelling the GIPR agonist versus antagonist paradox
Nature Metabolism,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 29, 2025
Язык: Английский
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(11), С. 3812 - 3812
Опубликована: Май 29, 2025
Emerging
clinical
data
support
the
paradoxical
notion
that
glucose-dependent
insulinotropic
polypeptide
(GIP)
receptor
(GIPR)
agonism
and
antagonism
can
provide
additive
weight
loss
when
combined
with
a
glucagon-like
peptide
1
(GLP-1)
(GLP-1R)
agonist.
In
this
review,
we
examine
motivated
initiation
of
these
seemingly
contradictory
drug
discovery
programs.
We
focus
on
physiologic
role
GIP
in
humans,
human
genetics
evidence,
rodent
genetic
models,
preclinical
non-human
primate
pharmacology
studies.
Furthermore,
highlight
where
early
findings
translated
into
relevant
efficacy
development
tirzepatide
maridebart
cafraglutide
(MariTide).
Язык: Английский